Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05653388 · ClinicalTrials.gov registry record
Metastatic Leiomyosarcoma Biomarker Protocol
A clinical trial of Leiomyosarcoma, sponsored by University of Michigan Rogel Cancer Center.
- Recruiting
- Registry status
- 200
- Enrollment target
- 11
- Study locations
NCT05653388: Recruiting study of Leiomyosarcoma, sponsored by University of Michigan Rogel Cancer Center.
NCT05653388 is a study of Leiomyosarcoma that is actively recruiting participants, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 200 participants, above the 109-participant average among 16 other Leiomyosarcoma trials with a reported enrollment target (83% higher). The trial reports 11 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05653388, a study of Leiomyosarcoma, is actively recruiting participants, sponsored by University of Michigan Rogel Cancer Center.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 11
- Study locations
Study Summary
Leiomyosarcoma (LMS) is one of the most prevalent soft tissue sarcomas (STS) and can occur in various sites including soft tissue, uterus and retroperitoneal large vessels. Metastatic disease occurs in approximately 50% of patients diagnosed with leiomyosarcoma and prognosis is poor in setting of metastatic disease. A minority of patients benefit from treatment with chemotherapy and early biomarkers of benefit from treatment are lacking. A biomarker of tumor response and patient survival benefit from chemotherapy early in the course of chemotherapy would be of significant impact in treatment planning. Circulating tumor DNA (ctDNA) is present in blood of patients with advanced/metastatic cancer and may serve as biomarker of tumor response to chemotherapy. Blood samples will be collected prior to and during and chemotherapy, and analyzed for ctDNA and for mutations in genes that are associated with increased risk of developing sarcoma. Tumor tissue will be collected and analyzed for changes in genes. Digital images of the sarcoma from CT or MRI scans obtained during treatment will be obtained for advanced radiomic analysis. Study participants will be asked to complete a questionnaire on attitudes and understanding of genetics and genetic testing.
Primary Outcome
To examine the correlation of change in ctDNA with objective tumor response per RECIST. Analysis will occur at each subsequent early time-point (pre-cycle 1 and pre-cycle 2).
Conditions Studied
Interventions
- OTHER Plasma Collection
Study Locations (11)
California
- Sarcoma Oncology Research Center - Santa Monica
Florida
- University of Miami - Miami
Massachusetts
- Dana- Farber - Boston
Michigan
- University of Michigan Cancer Center - Ann Arbor
Minnesota
- Mayo Clinic - Rochester
New York
- Memorial Sloan Kettering Cancer Center - New York
Ohio
- Ohio State University - Columbus
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2022-12-22 |
| Est. Completion | 2026-12 |
What NCT05653388 shows while recruiting
NCT05653388 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 109-participant average among 16 other Leiomyosarcoma trials with a reported enrollment target (83% higher).
The record links to 1 condition, with Leiomyosarcoma appearing as the primary indexed condition, and to 1 intervention - of which Plasma Collection is the first listed.
NCT05653388 lists 11 locations in 11 states (California, Florida, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT05653388 about?
NCT05653388 is a clinical study titled "Metastatic Leiomyosarcoma Biomarker Protocol". Leiomyosarcoma (LMS) is one of the most prevalent soft tissue sarcomas (STS) and can occur in various sites including soft tissue, uterus and retroperitoneal large vessels. Metastatic disease occurs in approximately 50% of patients diagnosed with leiomyosarcoma and prognosis is poor in setting of me...
What is the current status of trial NCT05653388?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2022-12-22. Estimated completion is 2026-12.
What conditions does trial NCT05653388 study?
This clinical trial studies the following conditions: Leiomyosarcoma.
What interventions are being tested in trial NCT05653388?
The interventions under investigation include: Plasma Collection (OTHER).
Who is sponsoring clinical trial NCT05653388?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05653388 being conducted?
This trial has 11 study locations across California, Florida, Massachusetts, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leiomyosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05653388's enrollment target sits among peer trials
200 5th of 16 higher than 12 of 16 other Leiomyosarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Leiomyosarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Localized Leiomyosarcoma Biomarker Protocol
RECRUITING
-
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
RECRUITING · Phase 3
-
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
RECRUITING · Phase 3
-
Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma
RECRUITING · Phase 2
-
Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma
RECRUITING · Phase 2
-
A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI